Tuesday, August 20, 2024

Electric Aviation Market Estimated to Reach $37 Billion By 2030 as Demand for Environment-Friendly Aircraft Rises; (NYSE: $KULR) (NASDAQ: $META) (NASDAQ: $NVDA) (NASDAQ: $NNE) (NYSE: $OKLO) @FNMgroup @KULRTech

Electric Aviation Market Estimated to Reach $37 Billion By 2030 as Demand for Environment-Friendly Aircraft Rises; (NYSE: $KULR) (NASDAQ: $META) (NASDAQ: $NVDA) (NASDAQ: $NNE) (NYSE: $OKLO) @FNMgroup @KULRTech

 


Palm Beach, FL – August 20, 2024 – FN Media Group News Commentary – According to the International Energy Agency (IEA), global flights produced around 720 million tons of carbon dioxide in 2021. The global aviation industry produces over 2% of all the CO2 emissions induced by humans.  With an increase in the number of global aircraft fleet size and air travel, these numbers are expected to rise even higher. Hence, there has been a pressing need for electric aircraft, which will help reduce the carbon footprint of the aviation industry. Organizations and governing bodies such as the International Civil Aviation Organization, the Federal Aviation Administration, and the European Union Aviation Safety Agency have called for sustainable alternatives to aircraft fuel as they estimate that aircraft-generated emissions are expected to be three-fold in volume by 2050. Since electric engines do not have noises associated with jet or combustion engines, they result in no aircraft noise levels. In an electric aircraft, manufacturers aim to improve efficiency by replacing hydraulically controlled systems with electric systems.  A report from MarketsAndMarkets projected that the Electric Aircraft Market which was valued at $8,800 Million in 2022 and is estimated to grow from $10,100 Million USD in 2023 to $37,200 Million USD by 2030 at a CAGR (Compound Annual Growth Rate) of 19.8%. Rising demand for environment-friendly aircraft and the growing development of UAVs and electric VTOLs are the key factors driving the electric aircraft market.  Active companies in news today include:  KULR Technology Group, Inc. (NYSE: KULR), Meta Platforms, Inc. (NASDAQ: META), NVIDIA Corporation (NASDAQ: NVDA), NNE NANO Nuclear Energy Inc. (NASDAQ: NNE), Oslo Inc. (NYSE: OKLO).

 

The MarketsAndMarkets report said: “An electric aircraft uses batteries for power and propulsion, which is traditionally achieved by fossil fuels. There has been a growing need for sustainable alternatives to fossil fuel to reduce the carbon emissions resulting from aircraft, as the global aircraft fleet size and air travel is expected to increase in the future. Electric aircraft are more energy-efficient and are considered a cleaner and quieter mode of air travel. Recent technological advancements in power electronics, battery technologies, and electrical motors played a major role in driving the market for electric aircraft. The adoption of electric aircraft is expected to drive value and unlock significant improvements in terms of aircraft weight, energy efficiency, total life cycle cost, maintenance, and aircraft reliability.  By system, the aerostructures segment is estimated to dominate the electric aircraft market during the forecast period. Aerostructures account for the largest share of the total development cost of an aircraft. Newly developed electric aircraft, especially eVTOL aircraft, require some of the most advanced materials to make them lightweight while maintaining their structural strength. These factors contribute to the large share of the system segment in the electric aircraft market.”

 

KULR Technology Group, Inc. (NYSE American: KULR) Partners with Amprius Technologies to Develop Reference Design to Enhance Battery Safety and Performance in Advanced Air Mobility – KULR Technology Group, (the “Company” or “KULR”), a global leader in safe and high-performance energy storage solutions, today announced it has been selected for a pivotal battery pack reference design project by Amprius Technologies (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform. The final reference design will provide Amprius’ customers with a solution to address thermal runaway at the battery pack level that leverages KULR’s advanced energy management platform, KULR ONE Design Solutions, with Amprius’ high-energy Silicon Anode pouch cells to meet the rigorous thermal qualification standards set by the Federal Aviation Administration (FAA) and European Union Aviation Safety Agency (EASA), ensuring the highest levels of safety and performance. This partnership is set to push the boundaries of next-generation battery technology, with a focus on the burgeoning advanced air mobility (AAM) market.

 

Read this in full at https://www.financialnewsmedia.com/electric-aviation-market-estimated-to-reach-37-billion-by-2030-as-demand-for-environment-friendly-aircraft-rises/

 

The integration of all lithium-ion battery technology into Advanced Air Mobility (AAM) presents significant challenges, particularly due to the risks of cell thermal runaway. To address these concerns, the FAA and EASA have established stringent design regulations to mitigate the risks associated with using lithium-ion battery packs in electric manned applications. The partnership between Amprius and KULR is designed to meet these strict safety standards and accelerate the adoption of Amprius’ high-performance cells in the AAM sector, where their technology is uniquely positioned to excel.

 

Driving Innovation in Battery Technology – The joint effort will explore innovative methods to enhance battery safety and maximize energy density at the pack level. By integrating KULR’s advanced thermal management solutions with Amprius’ high-energy and high-power lithium-ion batteries and cutting-edge silicon anode technology, the partnership aims to deliver a battery system that is not only safe but also exceptionally high-performance.

 

“KULR’s proven expertise in thermal management and energy storage solutions makes them an ideal partner for this project,” said Jon Bornstein, President of Amprius Technologies Lab. “By combining Amprius’ advanced silicon anode battery technology with KULR’s innovative approach to safety and performance, we are setting a new standard in the advanced air mobility segment. This partnership accelerates our ability to meet the stringent requirements of the electric aviation industry while simultaneously pushing forward the evolution of battery technology with a focus on safety, efficiency, and market expansion.” CONTINUED…  Read this entire press release and more news for KULR at:  https://www.financialnewsmedia.com/news-kulr/  

 

In addition to its battery technologies, KULR has a long history of serving the aviation industry with its KULR VIBE technology which eliminates vibration for helicopters and drones. Last week during they earnings call, KULR’s CEO was very excited how KULR VIBE serves the computer server market for Facebook (NASDAQ: META) and Nvidia (NASDAQ: NVDA) with better cooling technology by removing vibration in the server’s fans. KULR VIBE can reduce energy use and cool the hot AI processing chips more efficiently, which has dramatically increased energy demand for companies like NNE NANO Nuclear Energy Inc. (NASDAQ: NNE) and Oslo Inc. (NYSE: OKLO), which is backed by Sam Altman of OpenAI.

 

In other developments in the markets of note:

 

 

 

NVIDIA Corporation (NASDAQ: NVDA) recently announced major advancements to Universal Scene Description, or OpenUSD, that will expand adoption of the universal 3D data interchange framework to robotics, industrial design and engineering, and accelerate developers’ abilities to build highly accurate virtual worlds for the next evolution of AI.

 

Through new OpenUSD-based generative AI and NVIDIA-accelerated development frameworks built on the NVIDIA Omniverse™ platform, more industries can now develop applications for visualizing industrial design and engineering projects, and for simulating environments to build the next wave of physical AI and robots.

 

Meta Platforms, Inc. (NASDAQ: META) recently reported financial results for the quarter ended June 30, 2024.  “We had a strong quarter, and Meta AI is on track to be the most used AI assistant in the world by the end of the year,” said Mark Zuckerberg, Meta founder and CEO. “We’ve released the first frontier-level open source AI model, we continue to see good traction with our Ray-Ban Meta AI glasses, and we’re driving good growth across our apps.”

 

NANO Nuclear Energy Inc. (NASDAQ: NNE), a vertically integrated advanced nuclear energy and technology company developing portable clean energy solutions, recently announced that it has signed a Memorandum of Understanding (MOU) with the Rwanda Atomic Energy Board (RAEB).

 

The MOU establishes a framework under which NANO Nuclear work alongside the RAEB to facilitate the introduction and eventual integration of small modular reactors (SMRs) and microreactors, like ‘ZEUS’ and ‘ODIN’, NANO Nuclear’s next generation microreactors in development, throughout the Republic of Rwanda. NANO Nuclear will also be responsible for enabling the development of the country’s entire ecosystem of nuclear energy systems. This includes providing technical assistance, training and educational programs to develop Rwanda’s technical expertise in the nuclear energy industry.

 

Oklo Inc. (NYSE: OKLO), a fast fission clean power technology and nuclear fuel recycling company, recently announced a key strategic development in its supply chain management by signing a Preferred Supplier Agreement with Siemens Energy for the power conversion system of the Aurora powerhouse. This agreement underscores Oklo’s ambitions to bring cost-efficient advanced fission technology to market. Building on a previously signed Memorandum of Understanding, this binding agreement marks a crucial step in Oklo’s vision to enhance production scalability, cost efficiency, and rapid deployment to meet growing customer demand.

 

Siemens Energy is a supplier of steam turbine and generator technology – rotating equipment that is part of the conventional island in small and large nuclear generation plants. Siemens Energy will supply the power conversion and supporting systems, fostering efficiencies through economies of scale. Standardizing equipment across Oklo’s powerhouses is expected to result in cost savings in manufacturing, construction, operations, and maintenance. Utilizing shared spare parts across deployment is expected to reduce maintenance downtime, enhance reliability, and improve overall performance.

 

About FN Media Group:

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #tickertagpressreleases #pressreleases

 

Follow us on Facebook to receive the latest news updates: https://www.facebook.com/financialnewsmedia

 

Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup

 

Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

 

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated forty two hundred dollars for news coverage of the current press releases issued by KULR Technology Group, Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

 

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

 

SOURCE: FN Media Group

Breaking Renewable Energy Stock News: KULR (NYSE: $KULR) Partners with Amprius Technologies to Develop Reference Design to Enhance Battery Safety and Performance in Advanced Air Mobility; @KULRTech

Breaking Renewable Energy Stock News: KULR (NYSE: $KULR) Partners with Amprius Technologies to Develop Reference Design to Enhance Battery Safety and Performance in Advanced Air Mobility; @KULRTech

 


SAN DIEGO, CA - August 20, 2024 (Investorideas.com Newswire) KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in safe and high-performance energy storage solutions, today announced it has been selected for a pivotal battery pack reference design project by Amprius Technologies (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform. The final reference design will provide Amprius' customers with a solution to address thermal runaway at the battery pack level that leverages KULR's advanced energy management platform, KULR ONE Design Solutions, with Amprius' high-energy Silicon Anode pouch cells to meet the rigorous thermal qualification standards set by the Federal Aviation Administration (FAA) and European Union Aviation Safety Agency (EASA), ensuring the highest levels of safety and performance. This partnership is set to push the boundaries of next-generation battery technology, with a focus on the burgeoning advanced air mobility (AAM) market.

 

The integration of all lithium-ion battery technology into Advanced Air Mobility (AAM) presents significant challenges, particularly due to the risks of cell thermal runaway. To address these concerns, the FAA and EASA have established stringent design regulations to mitigate the risks associated with using lithium-ion battery packs in electric manned applications. The partnership between Amprius and KULR is designed to meet these strict safety standards and accelerate the adoption of Amprius' high-performance cells in the AAM sector, where their technology is uniquely positioned to excel.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of KULR Technology Group, Inc.

 

Read this news, featuring KULR in full at

https://www.investorideas.com/news/2024/08201KULR-Amprius-Technologies.asp

 

Driving Innovation in Battery Technology
The joint effort will explore innovative methods to enhance battery safety and maximize energy density at the pack level. By integrating KULR's advanced thermal management solutions with Amprius' high-energy and high-power lithium-ion batteries and cutting-edge silicon anode technology, the partnership aims to deliver a battery system that is not only safe but also exceptionally high-performance.

 

"KULR's proven expertise in thermal management and energy storage solutions makes them an ideal partner for this project," said Jon Bornstein, President of Amprius Technologies Lab. "By combining Amprius' advanced silicon anode battery technology with KULR's innovative approach to safety and performance, we are setting a new standard in the advanced air mobility segment. This partnership accelerates our ability to meet the stringent requirements of the electric aviation industry while simultaneously pushing forward the evolution of battery technology with a focus on safety, efficiency, and market expansion."

 

A Comprehensive Approach to Design and Testing
The project will be executed in four phases, beginning with extensive data collection and design concept delivery. Subsequent phases will include detailed thermal modeling, propagation prevention response (PPR) design, and rigorous testing to ensure compliance with the highest safety standards. This systematic approach will enable the development of a robust and scalable battery solution tailored to the needs of various applications within the e-aviation sector and beyond.

 

A Commitment to Market Expansion
This collaboration underscores KULR and Amprius' commitment to expanding into growing markets by providing innovative solutions that address the critical needs of safety and performance in energy-dense battery systems. The partnership is poised to play a pivotal role in the evolution of battery technology, particularly in the electric aviation market, where the demand for lightweight, high-performance energy storage solutions is rapidly increasing.

 

Precision Business Insights estimates the global electric aircraft market to reach USD $13.55 billion by 2030, growing at a CAGR of 7.62% during the forecast period of 2024 to 2030.

 

About KULR Technology Group, Inc.
KULR Technology Group Inc. (NYSE American: KULR) is a leading energy management platform company offering proven solutions that play a critical role in accelerating the electrification of the circular economy. Leveraging a foundation in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems, KULR has evolved its holistic suite of products and services to enable its customers across disciplines to operate with efficiency and sustainability in mind. For more information, please visit 
www.kulrtechnology.com.

 

About Amprius Technologies, Inc.
Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries, producing the industry's highest-known energy density cells. The company's commercially available SiMaxx™ batteries deliver up to 450 Wh/kg and 1,150 Wh/L, with third-party validation of 500Wh/kg and 1,300 Wh/L. Amprius expanded its product portfolio to include the SiCore™ platform in 2024, significantly enhancing its ability to serve additional customer applications. The company's corporate headquarters is in Fremont, California, where it maintains an R&D lab and a MWh scale manufacturing facility for the fabrication of silicon anodes and cells. To serve customer demand, Amprius entered into several agreements to secure over 500MWh of contract manufacturing available today and entered into a lease agreement for a GWh scale facility in Brighton, Colorado. For additional information, please visit 
amprius.com. Also, see the company's LinkedIn and Twitter pages.

 

Safe Harbor Statement
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on April 12, 2024, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management's best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether because of new information, future events or otherwise.

 

Investor Relations:
KULR Technology Group, Inc.
Phone: 858-866-8478 x 847
Email: 
ir@kulrtechnology.com

 

KULR Technology Group, Inc. (NYSE: KULR) is a featured renewable energy stock on Investorideas.com

 

More info on KULR at Investorideas.com Visit: https://www.investorideas.com/CO/KULR/

 

Disclaimer/Disclosure: Disclosure: (NYSE: KULR) is a paid featured company on Investorideas.com effective July 2024 for 3 months. lInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. More disclosure info can be found here. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 



Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

Friday, August 16, 2024

New Mining, Tech, Automotive and Cleantech Stocks; (TSXV: $MOG.V) (TSXV: $WMS.V) (CSE: $DD.CN) (NASDAQ: $SERV) (Nasdaq: $CREV) (ASX: $CPV.AX) (ASX: $DEL.AX)

New Mining, Tech, Automotive and Cleantech Stocks; (TSXV: $MOG.V) (TSXV: $WMS.V) (CSE: $DD.CN) (NASDAQ: $SERV) (Nasdaq: $CREV) (ASX: $CPV.AX) (ASX: $DEL.AX)

 

 



 

 

August 16, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Mining, Tech, Automotive and Cleantech sectors.  

 

The newest mining companies are all Canadian-listed with operations in Canada and Latin America.

 

The latest tech companies use AI in robotics and fintech, respectively, while the newest automotive company manufactures carbon fiber wheels for vehicles.

 

The newest cleantech companies provide solar technologies and bioenergy infrastructure in Australia.

 

Read this in full at https://www.investorideas.com/news/2024/main/08161Stocks.asp

 

Investor Ideas is always on the hunt for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector. 

 

New Stocks Added to the Mining Directories:

Mogotes Metals Inc. (TSXV:MOG) is an exploration company looking for copper and gold in the Vicuña district of Argentina and Chile. The flagship project, Filo Sur, is on strike with the Filo del Sol discovery, and in the same district as the NGEx Minerals Lunahuasi and Los Helados deposits.

 

Western Metallica Resources Corp. (TSXV: WMS) is in the business of mineral resource exploration and development and holds the options to acquire a 100% interest in two copper projects in Peru: Caña Brava, in La Libertad Province, and Turmalina, in Piura Province. Western Metallica is also advancing its 100% owned Nueva Celti Copper Property in the Ossa Morena belt in Andalusia, Spain, and three other Spanish gold projects in the “Navelgas Gold Belt” in Asturias, Spain (Penedela, Valledor and Sierra Alta).

 

Double Deuce Exploration Corp. (CSE:DD) is engaged in the business of acquisition and exploration of mineral properties in Canada. The Issuer holds an option to acquire an undivided 100% interest in and to mineral claims totaling 2,231.03 hectares comprising the Kimber Property located near Kimberley, British Columbia, subject to a royalty obligation. The Issuer’s secondary  objective is to locate and develop economic precious and base metals properties of merit.

 

New Stocks Added to the Tech Directories:

Serve Robotics Inc. (NASDAQ: SERV) develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. Serve has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets.

 

New Stocks Added to the Automotive/Transportation Directories:

Carbon Revolution plc (Nasdaq: CREV) is the parent of Carbon Revolution Pty Ltd, an early-stage growth company which has successfully innovated, commercialized and industrialized the advanced manufacture of carbon fiber wheels for the global automotive industry. The Company has progressed from single prototypes to designing and manufacturing lightweight wheels for cars and SUVs in the high performance, premium and luxury segments, for the world’s most prestigious automotive brands. Carbon Revolution is creating a significant and sustainable advanced technology business that supplies its lightweight wheel technology to automotive manufacturers around the world.

 

New Stocks Added to the Cleantech Directories:

ClearVue Technologies Ltd (ASX:CPV) is an Australian technology company that operates in the Building Integrated Photovoltaic (BPIV) sector which involves the integration of solar technology into building surfaces, specifically glass and building façades, to provide renewable energy. ClearVue has developed advanced glass technology that aims to preserve glass transparency to maintain building aesthetics whilst generating electricity.

ClearVue’s electricity-generating glazing technology is strategically positioned to complement and make more compelling, the increased use of energy-efficient windows now being regulated in response to global climate change and energy efficiency goals.

Solar PV cells are incorporated around the edges of an Insulated Glass Unit (IGU) used in windows and the lamination interlayer between the glass in the IGU incorporates ClearVue’s patented proprietary nano and micro particles, as well as its spectrally selective coating on the rear external surface of the IGU. ClearVue’s window technology has application for use in the building and construction and agricultural industries (among others). ClearVue has worked closely with leading experts from the Electron Science Research Institute, Edith Cowan University in Perth, Western Australia to develop the technology.

 

Delorean Corporation Ltd (ASX:DEL) is a leading Australian bioenergy company. Delorean specialises in the design, build, ownership, and management of bioenergy infrastructure. In addition to bioenergy power and renewable gas generation, Delorean also operates in the energy retail market. Delorean Corporation is a vertically integrated company positioned in two high growth industries; renewable energy and waste management. Delorean Corporation comprises an Engineering Division, Infrastructure Division, and legacy Energy Retail Division. Through these divisions Delorean Corporation has the inhouse capability to deliver bioenergy projects across the full lifecycle, from project conception to completion, processing organic waste, generating renewable energy, and monetising the sale of green electricity, heat, and gas. DEL’s projects produce renewable energy whilst reducing the volume of organic waste going to landfill, utilising a model that generates multiple revenue streams.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X)  https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411


 

 


 

 

 

 

 

 

Wednesday, August 14, 2024

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

 

Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024

 

Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023

 

Conference Call to be Held Today at 4:30 p.m. ET

 


SAN DIEGO, CA - August 14, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2024 and provided an update on recent developments.

 

Company Updates

Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applications in oncology, where cancer associated exosomes may promote immune suppression and metastasis, in life-threatening infectious diseases, and in organ transplantation.

 

As announced on August 12, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck's Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia.

 

Earlier, on June 18, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.

 

Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/08141AEMD-Fiscal-Q1.asp

 

"During the fiscal first quarter and subsequent period, we have continued to make significant progress advancing towards our planned oncology trials in Australia and India, punctuated by the recent approval from the Bellberry Human Research Ethics Committee (BHREC), which granted full ethics approval to the Pindara Private Hospital and earlier from the Human Research Ethics Committee at Central Adelaide Local Health Network, in June, for a safety, feasibility and dose-finding clinical trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical."

 

"Going forward, the next steps are to receive approval from the Research Governance Office at each hospital, which reviews indemnities and insurance. Once these approvals are obtained, Aethlon, in concert with our Australian Contract Research Organization, ReSQ, will conduct Site Initiation Visits (SIVs), after which patient enrollment in the trials may proceed. We expect that we will be open for enrollment in October 2024."

 

Mr. Frakes continued, "We anticipate several upcoming, potential value-creating milestones, including submission to the Ethics Committees at a third site in Australia and one in site in India, with the expectation of possibly receiving approval from one or both of those hospitals in the September or December quarter of 2024.  After approval is granted, we expect to be able to enroll patients at those additional sites by the end of 2024."

 

As a reminder, the primary endpoint of the approximate 9 to 18-patient, safety, feasibility and dose-finding trial, is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 antibody therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of subsequent efficacy and safety trials, including a Premarket Approval (PMA) study required by the FDA and other regulatory agencies.

 

The company continues to explore opportunities to expand the use of the Hemopurifier as a treatment for life-threatening viral infections. In vitro, it has shown effectiveness in capturing viruses such as Zika, Lassa, MERS-CoV, cytomegalovirus, Epstein-Barr, Herpes simplex, Chikungunya, Dengue, West Nile, smallpox-related viruses, H1N1 swine flu, H5N1 bird flu, Monkeypox, and the reconstructed 1918 Spanish flu virus. The company's COVID-19 trial in India remains open to accommodate any potential COVID-19 admissions to the intensive care units at the two participating sites, Medanta Medicity Hospital and Maulana Azad Medical College. So far, one patient has been treated. The company is actively evaluating COVID-19 admissions and potential enrollment against the ongoing costs of maintaining the trial.

 

Financial Results for the Fiscal First Quarter Ended June 30, 2024

As of June 30, 2024, Aethlon Medical had a cash balance of approximately $9.1 million.

 

Consolidated operating expenses for the fiscal quarter ended June 30, 2024 were approximately $2.6 million compared to $3.4 million for the fiscal quarter ended June 30, 2023. This decrease of approximately $800,000, or approximately 24%, in the 2024 period was due to a decrease of approximately $600,000 in general and administrative expenses and a decrease of approximately $300,000 in professional fees partially offset by an increase in payroll and related expenses of approximately $100,000.

 

The $600,000 decrease in general and administrative expenses in the fiscal quarter ended June 30, 2024 was primarily due to a $447,000 decrease in supplies related to the purchase of raw materials for manufacturing of the Hemopurifier and for lab supplies.

 

The approximate $300,000 decrease in professional fees was primarily due to a $136,000 decrease in consulting expenses primarily related to termination of services with a contract manufacturing organization, a $110,000 decrease in scientific consulting, and a $78,000 decrease in legal fees relating to general corporate matters.

 

The approximate $100,000 increase in payroll and related was primarily due to an increase in separation expenses of approximately $300,000 related to the termination of an employee. That increase was offset by a decrease of $111,000 in stock-based compensation and an $89,000 decrease in general and administration personnel expense.

 

As a result of the factors noted above, the company's net loss decreased to approximately $2.6 million in the fiscal quarter ended June 30, 2024 from approximately $3.3 million in the fiscal quarter ended June 30, 2023.

 

The consolidated balance sheet for June 30, 2024, and the consolidated statements of operations for the fiscal quarters ended June 30, 2024 and 2023 follow at the end of this release.

 

Conference Call

Management will host a conference call today, Wednesday, August 14, 2024, at 4:30 p.m. ET to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

 

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10191735/fd44630e3d . Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

 

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

 

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through September 14, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3788019.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to, and obtain approval from, the additional Ethics Committees in Australia and India, including on the timeline expected by the Company; the Company's ability to initiate its planned oncology clinical trials in Australia and India, including on the timeline expected by the Company; the Company's ability to obtain approvals from Research Governance Offices at relevant hospitals and complete site initiation visits in a timely manner; the Company's ability to manage and successfully complete its clinical trials, if initiated; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's ability to maintain its Nasdaq listing; and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:

Jim Frakes

Interim Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

 

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

917-513-5303

 




Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 



Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories